SlideShare una empresa de Scribd logo
1 de 41
Descargar para leer sin conexión
LOWOVARIANRESPONSE
Prof.AboubakrElnashar
BenhauniversityHospital,Egypt
ABOUBAKRELNASHAR
CONTENTS
1.MEASUREOFSUCCESSofIVF
2.PREVALENCE
3.DEFINITION&CLASSIFICATION
4.CAUSE
5.PREDICTION
6.MANANAGEMENT
1.Challenging
2.Prognosis
3.Interventions
4.AccordingtoPOSEIDON
CONCLUSIONABOUBAKRELNASHAR
1.MEASUREOFSUCCESSofIVF
▪Cumulativelivebirthrate(CLBR)perstartedcycle
▪MostimportantmeasureofsuccessinIVF
[Maheshwarietal,2015]
▪NumberofoocytesretrievedafterCOS
▪Greatlyinfluencestheclinicaloutcome
[Drakopoulosetal,2016].
▪Optimizationoftheoocytenumberbasedonthe
ovarianreserveisessential.
ABOUBAKRELNASHAR
▪Theidealnumberofoocytes,whichshouldbe
retrievedafterCOStomaximizeLBRinfreshET
cycles:
▪10accordingtoVerbergetal.[2009]
▪13accordingtoVanderGaastetal.[2006],
▪15accordingtoSunkaraetal.[2011].
▪18accordingtoFatemietal.[2013]
▪Onaverage,then,10–15oocytes
ABOUBAKRELNASHAR
❑Idealnumberofoocytesaccordingto:
woman’sagetoobtainatleastoneeuploid
blastocyst
▪Aneuploidchromosomalconstitution
▪stronglyrelatedtothewoman’sage
▪representsthemainfactoraffectingembryo
reproductivecompetence[Capalboetal,2017].
▪Theclinicianshoulddecideatreatmentstrategy
thatgiveatleastoneeuploidblastocyst
ABOUBAKRELNASHAR
ThemeaneuploidblastocystratesperMIIoocyteaccordingtotherangesofmaternal
agehavebeenestimatedbasedonanaverage35%blastocystrateperMIIoocyte,
whichisindependentfrommaternalage(GENERAdataunderreview),andonthe
euploidyrateperblastocystreportedbyCapalboetal.[2017].
ABOUBAKRELNASHAR
Meannumberofoocytesneededtooptimizethelikelihoodofaeuploidblastocyst
ABOUBAKRELNASHAR
2.PREVALENCE
▪9-24%[Ubaldietal,2014].
▪dependsonthedefinition
▪Notahomogeneouspopulation
▪Increasing{manypatientspostponingconceptionsto
thelatethirtiesorevenbeyond40}.
ABOUBAKRELNASHAR
3.DEFINITION&CLASSIFICATION
▪41differentdefinitionsoutof47RCTs:
▪Managementverydifficulttocompare
▪Anidealtreatmenthasneverbeendefined.
(Polyzosetal,2011)
ABOUBAKRELNASHAR
❑Classesofpatientsaccordingtoovarianresponse:
1.Poorresponder:3orlessoocytesretrieved
2.Suboptimalresponder:4to9oocytesretrieved
3.Normalresponder:10–15oocytesretrieved
4.Hyperresponder:15ormoreoocytesretrieved.
▪Theexactclassificationofthepatientinoneof
thesegroupsisessentialtodefinethecorrectTT
[Polyzosetal,2008].
ABOUBAKRELNASHAR
BolognaCriteria2011
❑Atleast2of3featuresmustbepresent:
1.Age(≥40y)oranyotherriskfactorforPOR
2.PreviousPOR
(≤3oocyteswithaconventionalstimulationprotocol)
3.AbnormalORT
(AFC<5–7folliclesorAMH<0.5–1.1ng/ml).
❑2episodesofPOR
aftermaximalstimulationinabsenceofadvancedmaternalage
orabnormalORT.
ABOUBAKRELNASHAR
❑Criticisms
1.Populationwastooheterogenousin
1.Woman’sage
2.Oocytecompetence
3.Riskfactors.
2.Noclearcut-offofAFC&AMH
Valuesrangingfrom5-7forAFC&0.5-1.1ng/mLforAMH
3.Useof“othercauseofPOR”asoneofcriterion:
thesecriteriaimprecise.
{asovariansurgeryorhistoryofchemotherapyshouldbe
evaluatedseparatelynotincludedinthesamecategory}.
ABOUBAKRELNASHAR
POSEIDON(Humaidanetal,2017)
(Patient-OrientedStrategiesEncompassingIndividualizeDOocyteNumber)
Thegroupcomprises12opinionleadersinreproductivemedicinefrom7countries
▪Moredetailedstratificationforpatientsby
▪Reducedovarianreserveor
▪Lowresponsetoovarianstimulation.
▪Movingfromapoorovarianresponsetoalow
prognosisconcept
▪Consideringnotonlythe
▪Numberofoocytesretrieved,butalso
▪Age-relatedaneuploidyrateand
▪Ovarian‘sensitivity’toGnTABOUBAKRELNASHAR
▪4groupsbasedonoocytequantity&quality
ABOUBAKRELNASHARABOUBAKRELNASHAR
ABOUBAKRELNASHAR
PrevalenceofPOSEIDONpatientsattendingaFertilityClinic&
distributionbygroupcategory.
(Androfert:(N.=432)-year2017).
ABOUBAKRELNASHAR
4.CAUSESofdiminishedovarianreserve
•Itisunclearwhetherrepresentsapathologiccondition
resultingfrom:
1.Abnormallyrapidatresiainanormalpoolofoocytes.
2.Normalatresiaofanabnormallysmallinitialpoolofoocytes.
▪Ovarianaging:DOR
▪fewerfollicles,whichareinhypoxicenvironment&consistof
fewergranulosacells,withpossiblyimpairedfunction(Pelliceretal.
1998)
ABOUBAKRELNASHAR
1.Genetic
▪Abnormalities(45X,FMR-premutations)
▪PolymorphismofGnT&theirreceptors
▪LH-bsubunitvariant
▪GallelecarriersofacommonFSHreceptor
(FSHR)polymorphism(p.N680SA>G,rs6166)
2.Autoimmunedisorders,likeAddison’sdisease
3.Metabolic:Galactosemia
4.Infectious:Mumpsoophoritis
ABOUBAKRELNASHAR
5.Iatrogenic
▪Exposuretochemotherapy
▪Exposuretoradiotherapy
▪Previousovariansurgery
▪Salpingectomyforectopic,hydrosalpinx,etc
▪Uterinearteryembolization&ligation
6.Environmental:
▪Pollutants
▪Oxidativestress
▪Smoking
7.Idiopathic:Inoverhalfofthesepatients
ABOUBAKRELNASHAR
❑PreventionofDOR
▪Avoidsmoking
▪Carefulsurgicaltechnique&strictadherenceto
principlesofmicrosurgery
▪LODshouldbeavoidedinpatientswithlowAMH
eveniftheovariesarepolycysticinappearance.
▪Beforechemotherapyorradiotherapy:various
methodsoffertilitypreservation
▪Useofapoptosisinhibitorslikesphingosine-1-
phosphatehasbeenproposed.ABOUBAKRELNASHAR
5.IDENTIFICATIONOFPATIENTATRISK
PREDICTION
(Fiedler&Ezcurra,2012)
HighresponseLowresponse
164TotalAFC
40.5AMHng/ml
48.9FSHIU/L
ABOUBAKRELNASHAR
6.MANAGEMENT
6.1.Challenging
▪Doctor
▪Expectationsofsuccessfulpregnancyarelow
▪Guidelinesarelacking
▪CochraneSR:(Oudendijketal,2012)
▪insufficientevidencetosupporttheroutine
useofanyparticularinterventions
ABOUBAKRELNASHAR
▪Couple
1.CostofIVFishigher
▪Higheramountofdrugsadopted
▪RepeatTTcycles.
2.Emotional,physical,&financialdistress,
particularlywhenmultipleTTcyclesarerequired.
3.Drop-outamongtheaffectedpatientsishigh
ABOUBAKRELNASHAR
6.2.Prognosis(Oudendijketal,2012)
▪variesgreatlydependingon
▪Age
▪Numberofoocytesretrieved
ABOUBAKRELNASHAR
❑Follicle-to-oocyteindex(FOI)forpoorresponders.
(Alviggietal.2016)
▪PORischaracterizedbyareducednumberof
FolliclesOutputRate(FORT)
▪Reflectthedynamicnatureoffolliculargrowthin
responsetoCOS,comparedtothetraditional
markersofovarianreserve.
ABOUBAKRELNASHAR
6.3.INTERVENTIONS:Many:33
▪Mostpopularintervention(Papathanasiouetal,2016)
1.Antagonist:Mostcommonstrategy(Jeve,Bhandari,2016)
2.Microdoseflare
3.Longprotocol
4.LHadded
5.Letrozole+FSH+antagonist
6.DHEA
7.Short(flareup)protocol
8.Transdermaltestosterone
9.Growthhormone
10.HCGaddedatstimulation
ABOUBAKRELNASHAR
11.IncreaseofFSHdose
12.CC+FSH/HMG+-antagonist
13.LutealFSHstart
14.Estrogenforlutealsupport
15.Follicularflushing
16.Long-stopprotocol
17.FSH/HMGonly(noagonistor
antagonist)
18.FSHdose300IU
19.LateFSHstart
20.Metformin
21.Ultrashorta-antagonist
22.Modifiedflare
23.Low-doseaspirin
24.Naturalcycle
25.Mini-longprotocol
26.Step-downofFSHdose
27.Lutealphaseantagonist
28.Gameteintrauterinetransfer
29.Dayofembryotransfer
30.Early(Day1)FSHstart
31.FSHdose450IU
32.FSHdose600IU
33.ClomiphenecitrateonlyABOUBAKRELNASHAR
❑WhataretherecentTrends?(Papathanasiouetal,2016)
ABOUBAKRELNASHAR
▪Nostandardmanagement,intermsofprotocol&
drugs,hasbeendefined[Patrizioetal,2015].
▪Thebestprotocol
▪Noconsensus.
▪Debatedissue.
▪Lines:
I.COS:
1.Type2.dose3.protocol4.triggering
II.Addson
III.Lab
ABOUBAKRELNASHAR
I.Controlledovarianstimulation
1.Gnttype
❑RecFSH
▪Notimproveoutcome(Tarlatzisetal,2003)
▪InsufficientevidencetorecommendonetypeofGnt
overanother(Nardoetal,2013)
ABOUBAKRELNASHAR
2.Gntdose
❑Increasedose:
▪Littleornobenefit(Tarlatzisetal,2003)
▪Patientswhofailedtoconceivewith450 IU/dwill
notbenefitfromincreasingdoseto600 IU(Haaset
al.,2015)
▪ESHRE,2019:
▪Itisunclearwhetherahighergonadotrophindoseis
recommendedover150IUforpredictedpoor
responders.
▪Dose≥300IUisnotrecommendedforpredictedpoor
responders.ABOUBAKRELNASHAR
❑CochraneSR,2018
▪Nodifferenceinpregnancyoutcomesbetweenlow
dosesofGnT&GnTcombinedwithoral
compounds(CCorLet)comparedwithhighdoses
ofGnTinovarianstimulationregimensinPOR
ABOUBAKRELNASHAR
3.Protocol
1.NaturalcycleVslongagonistprotocols
▪Nodifference(Tarlatzisetal,2003)
▪Theuseofmodifiednaturalcycleisprobablynot
recommendedoverconventionalOSforpredictedpoor
responders(ESHRE,2019)
2.MildCOS(CC/Gn/GnRHan)Vslongagonist
Nodifference(Songetal,2016)
3.FlareupVslongagonistprotocol
▪Betterresults(Tarlatzisetal,2003)
▪Nodifference(Sunkaraetal,2007)ABOUBAKRELNASHAR
4.FlareupVsAntagonist/Letprotocol
Better(Songetal,2014)
5.GnRHa'stop'Vslongagonistprotocol
Nodifference(Tarlatzisetal,2003)
6.AntagonistVsflareupprotocols.
Better(Francoetal,2006)
ABOUBAKRELNASHAR
7.AntagonistVslongagonist
Better
Griesingeretal,2006
Francoetal,2006
Nodifference
Tarlatzisetal,2003
Sunkaraetal,2007
Puetal,2011
Xiaoetal,2013
Nardoetal,2013
Jeve,Bhandari,2016
ESHRE,2019
GnRHantagonistsandGnRHagonistsareequallyrecommended
forpredictedpoorresponders.ABOUBAKRELNASHAR
▪ESHRE,2019:
▪shouldonlybeusedinthecontextofclinicalresearchonly
▪canbeconsideredforurgentfertilitypreservationcycles.
8.Doublestimulation(Ubaldietal,2015)
ABOUBAKRELNASHAR
▪Sfakianoudisetal,SR&MA,2019
▪DuoStimiscorrelatedwithahighernumberof
▪Retrievedoocytes,matureMIIoocytes
▪Goodqualityembryos
▪incomparisontoconventionalstimulation.
▪LPStimulation
▪correlatedwithanequaloranevenhigher
overallperformanceincomparisontoFPS.
▪notcorrelatedwithahigheraneuploidyrate.
❖DuoStim
promisingtreatmentofPORpatientsbyenablinga
higheroocyteyieldduringasinglemenstrual
cycle.ABOUBAKRELNASHAR
4.Triggering.
❑DualTriggering
statisticallysignificantincreasein
▪numberofretrievedoocytes
▪matureoocytes
▪fertilizedembryos
▪PR
▪IR
▪newborn/transferredembryorate.
(Oliveiraetal,2016)
ABOUBAKRELNASHAR
II.Adjuvants
1.GH
Nosignificant
improvement.
▪Tarlatzisetal,2003
▪Yuetal,2015
▪ESHRE,2019:
▪UseofGHbeforeand/or
duringOSisprobablynot
recommendedforpoor
responders.
Significantimprovement
▪CochraneSystRev.2003
▪Kyrouetal,2009
▪Kolibianakisetal,2009
▪Jeve,Bhandari,2016
▪Lietal,2017
ABOUBAKRELNASHAR
❑Dose:
4-12IUofGHSConthedayofstimulation
❑Effects:
▪stimulatessteroidogenesis,folliculardevelopment&
responsivenesstoFSH(Jiaetal.1986).
▪ActssynergisticallywithFSH(Adashi&Rohan1993)
▪mayimprovethenumberofoocytes
❑Disadvantages:
Expensive&routineusecannotbejustified
(CochraneSR.2002)
ABOUBAKRELNASHAR
▪Clonidinetest
▪Clonidineactscentrallytostimulatealpha-adrenergic
receptors,whichareinvolvedinregulatingGHrelease.
▪SerumGHlevelsareobtainedatbaselineandat60
minutesand90minutesaftertheoraladministrationof
clonidine0.1mg/kg.
▪Clonidinenegative:failuretoincreaseGHconcentration
▪GHincreaseovarianresponse&generatedPRandLBRin
clonidinenegativePORpatientsbutnotinclonidine
positiveinfertilepatients
ABOUBAKRELNASHAR
2.DHEAsupplementation
Notbeneficial
▪Bosdouetal,2012
▪Narkwicheanetal,2013
▪CochraneSR,2015(excluding
biasedstudies)
▪Quinetal,2016
▪Jeve,Bhandari,2016
▪Qinetal,2017ofRCT
Beneficial
▪Fouany,Sharara,2013
▪Lietal,2015
▪CochraneSR,2015
▪Zhangetal,2016
▪CochraneSR,2019
▪ESHRE,2019:
▪UseofDHEAbeforeand/orduringOSisprobablynot
recommendedforpoorresponders.ABOUBAKRELNASHAR
▪Mildandrogen
▪Dose:75mg–100mg/d
foratleast12w
▪Effects:(Zhangetal,2016)
▪IncreaseinAMHlevels
▪DecreaseinbaselineFSH
▪Improvesoocytenumbers
▪embryoquality
▪spontaneousPR
▪IVFPR
▪Advantages:
▪Availableover
counter
▪Minimalside
effects
▪Inexpensive
ABOUBAKRELNASHAR
3.Transdermaltestoeterone
Beneficial
▪GonzálezComadranetal,2012
▪Bosdouetal,2012
▪Luoetal,2014
▪CochraneSR,2015
▪Jeve,Bhandari,2016
Insufficientevidence
▪Sunkaraetal,2011
ESHRE,2019:UseoftestosteronebeforeOSisprobablynot
recommendedforpoorrespondersABOUBAKRELNASHAR
4.rLH
Beneficial
▪CochraneSystRev.2007
▪Nardoetal,2013
Notbeneficial
▪Bosdouetal,2012
▪Fanetal,2013
▪Jeve,Bhandari,2016
ABOUBAKRELNASHAR
5.LutealphaseE2
Beneficial
▪Changetal,2013
▪Reynoldsetal,2013
ABOUBAKRELNASHAR
EstrogenPrimed
AntagonistProtocol
•Pretreatmentcycleisanaturalcycle(noBCP).
•Aboutaweekafterovulation
–GnRHan{preventprematurerecruitmentoffollicles}
–Estrogen
{providestheyoungfolliclesanoptimalconditiontogrowinthefuture}.
•Onday3ofthenextmenses.
–Stimulationmedicationsarestarted
ABOUBAKRELNASHAR
6.OCPpretreatment
▪Tarlatzisetal,2003
▪±helpovarianresponse.
❑Nardoetal,2013
▪GnRHancycles:
•AdverselyaffectsIVFoutcome
▪GnRHacycles.
•Noeffect
ABOUBAKRELNASHAR
7.Corticosteroids
▪Reducestheincidenceofpoorovarianresponse
(Tarlatzisetal,2003)
▪BritishFertilitySociety,2014
Thereislimitedevidence
ABOUBAKRELNASHAR
❑Dexamethasone
▪1mg/dorallytillretrieval
▪directlyinfluencegranulosacellsviaisoformorby
increasingGH&IGF-1
▪improvetheendometrialmicroenvironment.
(Smithetal.2000,Keayetal.2001)
ABOUBAKRELNASHAR
8.Nitricoxidedonors
▪Limiteddata(Tarlatzisetal,2003)
ABOUBAKRELNASHAR
9.Aromataseinhibitors
Notbeneficial
(fourtrials;n=223)(Jeve,Bhandari,2016)
▪ESHRE,2019:
▪Theadditionofletrozoletogonadotrophinsinstimulation
protocolsisprobablynotrecommendedforpredictedpoor
responders.
ABOUBAKRELNASHAR
10.COENZYMEQ10
▪Rationale:
▪Oxidativestress&mitochondrialdysfunctionare
possiblepathophysiologicalmechanisms
▪CoQ10antioxidant
▪enablesfortheelectrontransportinmitochondrial
respiration&oxidativephosphorylationnecessary
foradenosinetriphosphate(ATP)production
ABOUBAKRELNASHAR
▪CoQ10supplementationtoCOS
▪Improvedpatients’responsetoovulationinduction
▪Decreasedfetalaneuploidyinolderpatients(El
Refaeeyetal,2014).
▪POSEIDONclassificationgroup3(Xuetal,RCT,2018).
▪Pre-treatmentfor2monthsbeforeCOSforIVF
▪Moreoocyteswereretrieved
▪Fertilizationrate&numberofhigh-quality
embryoswashigher
▪HigherCPR&LBR/ETdidnotreach
statisticalsignificanceABOUBAKRELNASHAR
StudyTypeNuOutcome
Sfakianoudisetal,
2019,GynecolObstet
Invest.
Case
series
3Withina3-monthinterval,FSH
decreasedby67.33%,AMH
increasedby75.18%.improved
embryoquality.Natural
conceptionat24successfullive
birth.
Farimanietal,2019Case
series
19Themeannumbersofoocytes
beforeandafterPRPinjection
were0.64and2.1.Two
spontaneousconceptions.The
thirdcaseachievedclinical
pregnancy
11.Platelet-richplasma
▪Poorresponders
ABOUBAKRELNASHAR
StudyType
of
study
No
of
pt
outcome
Sillsetal,
2018,Gyn
endocrinology
Case
series
4Improvedovarianfunctioninallcases,
IncreaseAMH,DecreaseFSHorboth.IVF:
retrievalof5.3±1.3MIIoocytes.
Nataliiaetal,
2020,Rep
science
observ
ational
cohort
38Significantimprovementinhormonelevels;6
babieswereborn,10pregnancieswere
achieved,and4outofthe10werefromnatural
conception.
Singhetal,
2020,ESHRE
observat
ional
cohort
30NobenefitinincreasingAMH,AFC,ovarian
responsetoovarianstimulationorIVFoutcome
Melloetal,
2020.JAssist
ReprodGenet
Controll
edNon
R
46SignificantimprovementinFSH,AMHandAFC,
nochangeinthecontrolgroup.biochemical
(26.1%vs5.4%,P=0.02)andclinical
pregnancy(23.9%vs5.4%,P=0.03)were
higherinthePRPgroup,nodifferencein
miscarriageandLBR
▪Diminishedovarianreserve
ABOUBAKRELNASHAR
❑ZhangetalSR,2020
▪46trials,6312womenwere
▪WithregardtoCP:DHEAandCoQ10:significantlyhigher
▪Withregardtothenumberofretrievedoocytes:HCG,E2
andGHtreatmentshadthehighestnumber
▪Withregardtothenumberofembryostransferred:
Testosterone&GHtreatmentledtothehighestnumber
▪GH:highestE2levelontheHCGday
▪CC,letrozole&GHgroupsusedthelowestdosagesofGnT
▪CoQ10:lowestcancelationrate
ABOUBAKRELNASHAR
❖ForpatientswithPOR,COSprotocolsusingadjuvant
treatmentwithDHEA,CoQ10&GHshowedbetter
clinicaloutcomesintermsofachievingpregnancy&
lowerdosageofGnT
ABOUBAKRELNASHAR
III.Lab
1.Assistedhatching
Nobenefit(Tarlatzisetal,2003)
2.Embryotransferonday2Vsday3
improveCPR(Kyrouetal,2009)
3.Follicularflushing
▪Doesnotincreasenumberofretrievedoocytes
▪LowerIR&CPR(NeumannK,Griesinger,2017)
ABOUBAKRELNASHAR
6.4.TreatmentAccordingToThePOSEIDON
Stratification(Drakopoulosetal,2020)
Group1&2
▪G1:Youngwomen(<35years)withnormalovarian
markers(AMH1.2;AFC5)
▪G2:Oldwoman(>35years)withnormalovarian
markers(AMH1.2;AFC5)
▪Issue:Unexpectedpoorresponse:
-HyposensitivityofgranulosacellstostandardFSHdoses
-FSHreceptorpolymorphisms
ABOUBAKRELNASHAR
I.COS:
1.Protocol
▪BothGnRHlongagonist&antagonistprotocols
maybeused{studieshasshowncomparable
efficacy}
▪Theyperformbettercomparedwiththeshort
flare-upprotocol
ABOUBAKRELNASHAR
▪Dualstimulation
▪Giventhatoocyte&embryoaneuploidyratesare
higherinthisgroupcomparedwithwomen<35years:higher
oocyteyieldisrequiredtoobtainaneuploidembryo.
▪oocytes/embryosderivedfromlutealphasestimulation
showsimilarcompetenceasfollicularphasestimulation-
ones
▪Maximizingthetotalnumberofoocytesinonemenstrual
cycle:higherprobabilitytogetageneticallynormalembryo
:thecumulativeLBRwouldbeincreased.
ABOUBAKRELNASHAR
2.Typeofgonadotropins
▪{Themainproblembehindunexpected
suboptimal/poorresponseisthattheoocyteyieldis
notconsistentwithovarianreserve}
▪Toretrievemoreoocytes,amore“potent”GnT.
▪SeveralRCTs&meta-analyses:rFSH:significantly
moreoocytescomparedwithurinarypreparations
(Devroeyetal,2012;Santietal,2017)suggestingthat
rFSHmaybetheGnTofchoiceforPoseidon
groups1and2.
ABOUBAKRELNASHAR
3.Dose:Increaseofinitialdoseofstimulation
▪higherrFSHstartingdose(225IU)inwomenhomozygousforSer680(SS):significantlyhigherserum
E2comparedwithSSwomentreatedwithalower(150IU)doseandsimilarserumE2levelswith
womenhomozygousforAsn680(AA)/heterozygous(AS)treatedwith150IUofrFSH.
▪Anincreaseinthestimulationdoseofthesecond
IVFcycle:significantlyhigheroocyteyield.
▪Anincreaseby50unitsintheinitialdose:onemore
oocyte.
▪EachadditionaloocytemayincreasetheLBRby
5%(Martinetal,2010)
ABOUBAKRELNASHAR
II.Addson
▪rLHII.
▪To
▪stimulateearlystagesoffolliculargrowth
▪improveFSHreceptorexpressioningranulosacells
▪improvethesensitivitytoFSHdose&recruitability
▪MainlybenefitspatientswhoarecarriersofLH–β&
presentovarianresistancetoGnT.
▪showingabenefitintermsofoocyteyield&PR
▪2:1ratioofrFSH:LH,(75–150IUoncedaily)
▪Startingat
▪Mid-follicularphaseinanattempttorescuetheongoing
cycleor
▪fromday1ofthefollowingIVFcyle.
ABOUBAKRELNASHAR
▪Androgenssupplementation
▪DHEAsupplementationfor8weeksbeforeCOSwere
foundtohavesignificantlyhigherLBR&lowermiscarriage
rate(Tartagnietal,2013)
ABOUBAKRELNASHAR
Group3&4
G3:Youngwomen(<35years)withpoorovarianreserve
markers(AFC<5;AMH<1.2ng/ml)
G4:Oldwomen(>35years)withpoorovarianreserve
markers(AFC<5;AMH<1.2ng/ml)
▪Issue
DepletionofovarianreserveintermsofAFC
ABOUBAKRELNASHAR
I.COS
1.Protocol
▪AntagonistprotocolwithSynchronizingfolliclewave
beforestartingCOSwith
1.E2for5dayspriortomenses
2.ShortGnRHanpre-treatmentatbeginningofthe
cycle
3.Oralcontraceptives
4.Progestinsfor12–14daysaspretreatment
▪LongGnRHaprotocol,albeitnon-significantly,increasedthenumberofmature
oocytesbyoneoocyteascomparedwiththeGnRHanprotocol{follicular
synchronizationfollowinglutealFSHsuppression&inhibitionofearlyfollicular
recruitmentobtainedwithdownregulationusinganagonistprotocol}(Sunkaraet
al,2018)
ABOUBAKRELNASHAR
▪Doublestimulationinamenstrualcycle(DuoStim)
{Multiplefollicularwavesduringonemenstrualcyclehas
offerednewpossibilitiesforovarianstimulation}
ABOUBAKRELNASHAR
2.GnTtype:
▪insufficientevidencetofavortheuseofonetypeof
GnTratherthananotherinPOR(ESHRE,2019),making
thisdecisionsubjecttoavailability,convenience&
costs.
3.GnTdose:[Berkkanogluetal,2010].
▪FSH300IUdaily.
▪Higherdoseswillnevercompensatetheabsence
offollicles{GnTcanonlysupportthecohortoffollicle
responsivetothestimulation,butcannotgeneratefollicles
denovo}
ABOUBAKRELNASHAR
II.Addson
▪AddingLH:(Alviggietal,SR2018)
▪benefitwasmorepronouncedin
▪unexpectedPORs
▪women36–39yearsofage
▪whileitsuseingeneralPORpopulationremains
controversial
ABOUBAKRELNASHAR
▪Insignificantimprovetheovarianreserve.
▪Growthhormone[Eftekharetal,2013]
▪DHEA[Yeungetal,2016]
▪Testosterone[Bosdouetal,2016]
▪CoQ10:2mpriortoCOS(Zhangetal.,RCT2020)inPOSEIDON
group3
▪significantlyhighernumberofretrievedoocytes
▪SignificantlylessconsumedFSH
▪{CoQ10wouldreducemitochondrialoxidativestress:
improvedoocytecompetence}
ABOUBAKRELNASHAR
CONCLUSION
▪PoorprognosispatientschallengeIVFclinicians
▪Bolognacriteriadescribedaveryheterogenousgroup
withhighlydifferentsuccessratesafterART.
▪POSEIDONcriteriaforPOR,stratifyingpatientsinto
morehomogenoussub-groups,andimportantly,giving
recommendationsforclinicalTT.
▪TreatmentoftheexpectedPORpatientdemandsan
individualizedapproachincludingallstepsofART,pre-
treatmentstrategy,ovarianstimulationstrategyand
ovulationtriggerstrategyABOUBAKRELNASHAR
▪Despitethetwodecadesoftrying,thereisstillno
consensusonwhatisbestforpoorresponders
▪Nosingletreatmentcanberecommendedover
another,astheevidenceforallofthemisinsufficient.
ABOUBAKRELNASHAR
Youcangetthislecturefrom:
1.MyscientificpageonFacebook:Aboubakr
ElnasharLectures.
https://www.facebook.com/groups/2277448840913
51/
2.Slidesharewebsite
3.elnashar53@hotmail.com
4.Myclinic:Althwarast,Mansura
ABOUBAKRELNASHAR
▪Clomiphenecitratealoneorincombinationwithgonadotrophins
andgonadotrophinstimulationaloneisequallyrecommended
forpredictedpoorresponders.
▪NostudieswerefoundcomparingareducedFSHdose(<150
IU/day)toconventionalFSHstimulationinpoorresponders.
ABOUBAKRELNASHAR
▪Useofaspirinbeforeand/orduringOSisnotrecommendedin
thegeneralIVF/ICSIpopulationandforpoorresponders.
▪Useofsildenafilbeforeand/orduringOSisnotrecommended
forpoorresponders.
ABOUBAKRELNASHAR
▪Thefollowinginterventionsarepromising
{Littleevidence:Possiblyeffective:moreevidence
needed}
▪FlareupGnRHaprotocol
▪Dualtriggering
▪EstrogenPrimedAntagonistProtocol
▪GH
▪DHEAsupplementation
▪Transdermaltestoeterone
▪Embryotransferonday2
ABOUBAKRELNASHAR
▪Routineuseofadjuvantmetforminbeforeand/orduringOSis
notrecommendedwiththeGnRHantagonistprotocolfor
womenwithPCOS.
▪UseofadjuvantGHbeforeand/orduringOSisprobablynot
recommendedforpoorresponders.
▪UseoftestosteronebeforeOSisprobablynotrecommended
forpoorresponders.
▪Useofdehydroepiandrosteronebeforeand/orduringOSis
probablynotrecommendedforpoorresponders.
▪Useofaspirinbeforeand/orduringOSisnotrecommendedin
thegeneralIVF/ICSIpopulationandforpoorresponders.
▪Useofsildenafilbeforeand/orduringOSisnotrecommended
forpoorresponders.
▪Thereisnoevidence,i.e.controlledstudiesorrandomised
controlledstudies(RCTs),addressingtheefficacyandsafetyof
adjuvantindomethacinuse,tosupportarecommendationon
theuseofindomethacinduringOS.
ABOUBAKRELNASHAR
1.InPORpatientswithborderlineGHdeficiency
(Clonidinenegativepatients),theadditionofGHtoCOH
mayimproveIVFresults.
2.InPORpatientswithevidenceofautoimmunityto
variousglandsandorgans(thyroid,adrenal...),
suggestinganautoimmunepathophysiologytotheir
POR,aprotocolcombiningglucocorticoids,long
GnRHa,andhighdosegonadotropinsmayimprovethe
numberofretrievedoocytes,andpossiblyalsotheIVF
results.Evenincaseswherethere
wasasignificantincreaseintheyieldofgeneratedova
andembryabythisprotocol,themaximalrecommended
attemptsisthree—sinceallthepregnanciesachieved
byusingthiscombinationweresuccessfulwithinthree
attempts(1–3).
Inaddition,thepreliminaryoptimisticreportson
ABOUBAKRELNASHAR
1.SynchronizingfolliclewavebeforestartingCOSwith
E2,progestin,OCP
1.GnRHantagonist
2.IncreasingFSHdailydose
▪FSHdosedoesnotreachminimumthresholdforadequate
follicularrecruitment
4.AddingLH(75–150IUoncedaily)
▪Tostimulateearlystagesoffolliculargrowth
▪ToimproveFSHreceptorexpressioningranulosacells
▪ToimprovethesensitivitytoFSHdose&recruitability
ABOUBAKRELNASHAR
▪Ifahyporesponseisprecociouslydiagnosedin
groups1&2POSEIDON(days5–8ofCOS)
▪IncreaseofFSHdoseand
▪AddLHactivity
▪couldbeeffectiveinpreventinglowfollicular
outputrate(FORT).
ABOUBAKRELNASHAR

Más contenido relacionado

La actualidad más candente

Immunological issues in recurrent implant failure
Immunological issues in recurrent implant failureImmunological issues in recurrent implant failure
Immunological issues in recurrent implant failureArunSharma10
 
Recurrent implantation failure: British fertility society Guidelines2020
Recurrent implantation failure: British fertility society Guidelines2020Recurrent implantation failure: British fertility society Guidelines2020
Recurrent implantation failure: British fertility society Guidelines2020Aboubakr Elnashar
 
Management of Poor Responders
Management of Poor RespondersManagement of Poor Responders
Management of Poor RespondersSandro Esteves
 
Adenomyosis associated infertility: Review of systematic reviews
Adenomyosis associated infertility: Review of systematic reviewsAdenomyosis associated infertility: Review of systematic reviews
Adenomyosis associated infertility: Review of systematic reviewsAboubakr Elnashar
 
Strategies to improve ovarian stimulation
Strategies to improve ovarian stimulationStrategies to improve ovarian stimulation
Strategies to improve ovarian stimulationSandro Esteves
 
Top Five Problems You Have with Ovulation Induction and How to Solve Them
Top Five Problems You Have with Ovulation Induction and How to Solve ThemTop Five Problems You Have with Ovulation Induction and How to Solve Them
Top Five Problems You Have with Ovulation Induction and How to Solve ThemSandro Esteves
 
OVARIAN RESERVE DIAGNOSIS & MANAGEMENT DR Sharda Jain
OVARIAN RESERVE DIAGNOSIS & MANAGEMENT DR Sharda Jain OVARIAN RESERVE DIAGNOSIS & MANAGEMENT DR Sharda Jain
OVARIAN RESERVE DIAGNOSIS & MANAGEMENT DR Sharda Jain Lifecare Centre
 
Unnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicineUnnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicineAboubakr Elnashar
 
Managing poor responder
Managing poor responderManaging poor responder
Managing poor responderG A RAMA Raju
 
Optimal endometrial preparation for frozen embryo transfer cycles
Optimal endometrial preparation for frozen embryo transfer cyclesOptimal endometrial preparation for frozen embryo transfer cycles
Optimal endometrial preparation for frozen embryo transfer cyclesnermine amin
 
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANI
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANIEVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANI
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANIDR SHASHWAT JANI
 
Role of LH in Controlled Ovarian Stimulation
Role of LH in Controlled Ovarian StimulationRole of LH in Controlled Ovarian Stimulation
Role of LH in Controlled Ovarian StimulationSandro Esteves
 
Ovarian Stimulation Protocols
Ovarian Stimulation ProtocolsOvarian Stimulation Protocols
Ovarian Stimulation ProtocolsHesham Gaber
 
Thin Endometrium & Infertility
Thin Endometrium & InfertilityThin Endometrium & Infertility
Thin Endometrium & InfertilityLifecare Centre
 
platelet rich plasma in reproductive medicine
platelet rich plasma in reproductive medicineplatelet rich plasma in reproductive medicine
platelet rich plasma in reproductive medicineAboubakr Elnashar
 

La actualidad más candente (20)

Immunological issues in recurrent implant failure
Immunological issues in recurrent implant failureImmunological issues in recurrent implant failure
Immunological issues in recurrent implant failure
 
Recurrent implantation failure: British fertility society Guidelines2020
Recurrent implantation failure: British fertility society Guidelines2020Recurrent implantation failure: British fertility society Guidelines2020
Recurrent implantation failure: British fertility society Guidelines2020
 
ART PREGNANCY COMPLICATIONS
ART PREGNANCY COMPLICATIONSART PREGNANCY COMPLICATIONS
ART PREGNANCY COMPLICATIONS
 
Management of Poor Responders
Management of Poor RespondersManagement of Poor Responders
Management of Poor Responders
 
Individualization of COS
Individualization of COSIndividualization of COS
Individualization of COS
 
EMPTY FOLLICLE SYNDROME
EMPTY FOLLICLE SYNDROMEEMPTY FOLLICLE SYNDROME
EMPTY FOLLICLE SYNDROME
 
Adenomyosis associated infertility: Review of systematic reviews
Adenomyosis associated infertility: Review of systematic reviewsAdenomyosis associated infertility: Review of systematic reviews
Adenomyosis associated infertility: Review of systematic reviews
 
Strategies to improve ovarian stimulation
Strategies to improve ovarian stimulationStrategies to improve ovarian stimulation
Strategies to improve ovarian stimulation
 
Top Five Problems You Have with Ovulation Induction and How to Solve Them
Top Five Problems You Have with Ovulation Induction and How to Solve ThemTop Five Problems You Have with Ovulation Induction and How to Solve Them
Top Five Problems You Have with Ovulation Induction and How to Solve Them
 
OVARIAN RESERVE DIAGNOSIS & MANAGEMENT DR Sharda Jain
OVARIAN RESERVE DIAGNOSIS & MANAGEMENT DR Sharda Jain OVARIAN RESERVE DIAGNOSIS & MANAGEMENT DR Sharda Jain
OVARIAN RESERVE DIAGNOSIS & MANAGEMENT DR Sharda Jain
 
Unnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicineUnnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicine
 
Endometriosis and art
Endometriosis and artEndometriosis and art
Endometriosis and art
 
Fet endometrial preparation
Fet endometrial preparationFet endometrial preparation
Fet endometrial preparation
 
Managing poor responder
Managing poor responderManaging poor responder
Managing poor responder
 
Optimal endometrial preparation for frozen embryo transfer cycles
Optimal endometrial preparation for frozen embryo transfer cyclesOptimal endometrial preparation for frozen embryo transfer cycles
Optimal endometrial preparation for frozen embryo transfer cycles
 
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANI
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANIEVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANI
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANI
 
Role of LH in Controlled Ovarian Stimulation
Role of LH in Controlled Ovarian StimulationRole of LH in Controlled Ovarian Stimulation
Role of LH in Controlled Ovarian Stimulation
 
Ovarian Stimulation Protocols
Ovarian Stimulation ProtocolsOvarian Stimulation Protocols
Ovarian Stimulation Protocols
 
Thin Endometrium & Infertility
Thin Endometrium & InfertilityThin Endometrium & Infertility
Thin Endometrium & Infertility
 
platelet rich plasma in reproductive medicine
platelet rich plasma in reproductive medicineplatelet rich plasma in reproductive medicine
platelet rich plasma in reproductive medicine
 

Similar a update on poor responder

Effect of sperm morphology& number on success of IUI
Effect of sperm morphology& number on success of IUIEffect of sperm morphology& number on success of IUI
Effect of sperm morphology& number on success of IUIAboubakr Elnashar
 
ROLE OF CABERGOLIN IN MANAGEMENT OF OHSS
ROLE OF  CABERGOLIN  IN MANAGEMENT OF  OHSSROLE OF  CABERGOLIN  IN MANAGEMENT OF  OHSS
ROLE OF CABERGOLIN IN MANAGEMENT OF OHSSAboubakr Elnashar
 
Adjuncts in IVF laboratory: Current evidence
Adjuncts in IVF laboratory: Current evidenceAdjuncts in IVF laboratory: Current evidence
Adjuncts in IVF laboratory: Current evidenceAboubakr Elnashar
 
PERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHAR
PERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHARPERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHAR
PERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHARAboubakr Elnashar
 
ROLE OF CABERGOLIN IN MANAGEMENT OF OHSS
ROLE OF  CABERGOLIN  IN MANAGEMENT OF  OHSSROLE OF  CABERGOLIN  IN MANAGEMENT OF  OHSS
ROLE OF CABERGOLIN IN MANAGEMENT OF OHSSAboubakr Elnashar
 
OHSS: Prediction and prevention in non IVF cycles
OHSS:  Prediction and prevention in  non IVF cyclesOHSS:  Prediction and prevention in  non IVF cycles
OHSS: Prediction and prevention in non IVF cyclesAboubakr Elnashar
 
ART: Factors affecting success
ART:  Factors affecting  success ART:  Factors affecting  success
ART: Factors affecting success Aboubakr Elnashar
 
Recurrent implantation failure
Recurrent implantation failureRecurrent implantation failure
Recurrent implantation failureAboubakr Elnashar
 
Management of Endometrioma associated infertility
Management of Endometrioma associated infertilityManagement of Endometrioma associated infertility
Management of Endometrioma associated infertilityAboubakr Elnashar
 
Hysteroscopy Overview of systematic reviews
Hysteroscopy   Overview of systematic reviews Hysteroscopy   Overview of systematic reviews
Hysteroscopy Overview of systematic reviews Aboubakr Elnashar
 
Necrotizing enterocolitis in newborns
Necrotizing enterocolitis in newbornsNecrotizing enterocolitis in newborns
Necrotizing enterocolitis in newbornsDr Praman Kushwah
 
Induction of labour (2)
Induction of labour (2)Induction of labour (2)
Induction of labour (2)drmcbansal
 
Optimal Timing of Oocyte Preincubation for Intra Cytoplasmic Sperm Injection ...
Optimal Timing of Oocyte Preincubation for Intra Cytoplasmic Sperm Injection ...Optimal Timing of Oocyte Preincubation for Intra Cytoplasmic Sperm Injection ...
Optimal Timing of Oocyte Preincubation for Intra Cytoplasmic Sperm Injection ...theijes
 
Patient preparation before IVF
Patient preparation before IVFPatient preparation before IVF
Patient preparation before IVFAboubakr Elnashar
 
Induction of labour (2)
Induction of labour (2)Induction of labour (2)
Induction of labour (2)drmcbansal
 
Role of tubal surgery in era of ivf
Role of tubal surgery in era of ivfRole of tubal surgery in era of ivf
Role of tubal surgery in era of ivfSanjay Makwana
 
Role of tubal surgery in era of ivf
Role of tubal surgery in era of ivfRole of tubal surgery in era of ivf
Role of tubal surgery in era of ivfSanjay Makwana
 

Similar a update on poor responder (20)

Effect of sperm morphology& number on success of IUI
Effect of sperm morphology& number on success of IUIEffect of sperm morphology& number on success of IUI
Effect of sperm morphology& number on success of IUI
 
ROLE OF CABERGOLIN IN MANAGEMENT OF OHSS
ROLE OF  CABERGOLIN  IN MANAGEMENT OF  OHSSROLE OF  CABERGOLIN  IN MANAGEMENT OF  OHSS
ROLE OF CABERGOLIN IN MANAGEMENT OF OHSS
 
Infertility management 2019
Infertility management 2019Infertility management 2019
Infertility management 2019
 
Adjuncts in IVF laboratory: Current evidence
Adjuncts in IVF laboratory: Current evidenceAdjuncts in IVF laboratory: Current evidence
Adjuncts in IVF laboratory: Current evidence
 
PERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHAR
PERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHARPERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHAR
PERFORMING EMBRYO TRANSFER. ABOUBAKR ELNASHAR
 
ROLE OF CABERGOLIN IN MANAGEMENT OF OHSS
ROLE OF  CABERGOLIN  IN MANAGEMENT OF  OHSSROLE OF  CABERGOLIN  IN MANAGEMENT OF  OHSS
ROLE OF CABERGOLIN IN MANAGEMENT OF OHSS
 
OHSS: Prediction and prevention in non IVF cycles
OHSS:  Prediction and prevention in  non IVF cyclesOHSS:  Prediction and prevention in  non IVF cycles
OHSS: Prediction and prevention in non IVF cycles
 
ART: Factors affecting success
ART:  Factors affecting  success ART:  Factors affecting  success
ART: Factors affecting success
 
Recurrent implantation failure
Recurrent implantation failureRecurrent implantation failure
Recurrent implantation failure
 
OVARIAN RESERVE
OVARIAN RESERVEOVARIAN RESERVE
OVARIAN RESERVE
 
Management of Endometrioma associated infertility
Management of Endometrioma associated infertilityManagement of Endometrioma associated infertility
Management of Endometrioma associated infertility
 
Hysteroscopy Overview of systematic reviews
Hysteroscopy   Overview of systematic reviews Hysteroscopy   Overview of systematic reviews
Hysteroscopy Overview of systematic reviews
 
Necrotizing enterocolitis in newborns
Necrotizing enterocolitis in newbornsNecrotizing enterocolitis in newborns
Necrotizing enterocolitis in newborns
 
Induction of labour (2)
Induction of labour (2)Induction of labour (2)
Induction of labour (2)
 
Optimal Timing of Oocyte Preincubation for Intra Cytoplasmic Sperm Injection ...
Optimal Timing of Oocyte Preincubation for Intra Cytoplasmic Sperm Injection ...Optimal Timing of Oocyte Preincubation for Intra Cytoplasmic Sperm Injection ...
Optimal Timing of Oocyte Preincubation for Intra Cytoplasmic Sperm Injection ...
 
Patient preparation before IVF
Patient preparation before IVFPatient preparation before IVF
Patient preparation before IVF
 
Induction of labour (2)
Induction of labour (2)Induction of labour (2)
Induction of labour (2)
 
Role of tubal surgery in era of ivf
Role of tubal surgery in era of ivfRole of tubal surgery in era of ivf
Role of tubal surgery in era of ivf
 
Role of tubal surgery in era of ivf
Role of tubal surgery in era of ivfRole of tubal surgery in era of ivf
Role of tubal surgery in era of ivf
 
Embryo transfer lecture 7
Embryo transfer lecture 7Embryo transfer lecture 7
Embryo transfer lecture 7
 

Más de Aboubakr Elnashar

WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGISTWHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGISTAboubakr Elnashar
 
Adenomyosis associated infertility
Adenomyosis associated  infertilityAdenomyosis associated  infertility
Adenomyosis associated infertilityAboubakr Elnashar
 
Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022Aboubakr Elnashar
 
Aesthetic gynecology controversy
Aesthetic gynecology controversyAesthetic gynecology controversy
Aesthetic gynecology controversyAboubakr Elnashar
 
Hormonal assay in clinical gyn
Hormonal assay in clinical gynHormonal assay in clinical gyn
Hormonal assay in clinical gynAboubakr Elnashar
 
Individualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulationIndividualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulationAboubakr Elnashar
 
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA Aboubakr Elnashar
 
cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021  cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021 Aboubakr Elnashar
 
Management of pregnancy of unknown location
Management of pregnancy of unknown locationManagement of pregnancy of unknown location
Management of pregnancy of unknown locationAboubakr Elnashar
 
COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021Aboubakr Elnashar
 

Más de Aboubakr Elnashar (20)

WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGISTWHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
 
hepatitis B.pdf
hepatitis B.pdfhepatitis B.pdf
hepatitis B.pdf
 
hepatitis c2022.pdf
hepatitis c2022.pdfhepatitis c2022.pdf
hepatitis c2022.pdf
 
Adenomyosis associated infertility
Adenomyosis associated  infertilityAdenomyosis associated  infertility
Adenomyosis associated infertility
 
Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022
 
Adenxal mass guidelines2020
Adenxal mass guidelines2020Adenxal mass guidelines2020
Adenxal mass guidelines2020
 
Aesthetic gynecology controversy
Aesthetic gynecology controversyAesthetic gynecology controversy
Aesthetic gynecology controversy
 
Hormonal assay in clinical gyn
Hormonal assay in clinical gynHormonal assay in clinical gyn
Hormonal assay in clinical gyn
 
FIRST TRIMESTER ANC OF IVF
FIRST TRIMESTER ANC OF IVFFIRST TRIMESTER ANC OF IVF
FIRST TRIMESTER ANC OF IVF
 
Infertility prevention
Infertility prevention Infertility prevention
Infertility prevention
 
Individualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulationIndividualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulation
 
Female infertility
Female infertility Female infertility
Female infertility
 
Maternal near miss
Maternal near missMaternal near miss
Maternal near miss
 
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
 
cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021  cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021
 
CAESAREAN SCAR DEFECT
CAESAREAN SCAR DEFECT  CAESAREAN SCAR DEFECT
CAESAREAN SCAR DEFECT
 
Management of pregnancy of unknown location
Management of pregnancy of unknown locationManagement of pregnancy of unknown location
Management of pregnancy of unknown location
 
Aerobic Vaginitis
Aerobic Vaginitis Aerobic Vaginitis
Aerobic Vaginitis
 
COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021
 
Imaging in pregnancy 2 in1
Imaging in pregnancy 2 in1Imaging in pregnancy 2 in1
Imaging in pregnancy 2 in1
 

Último

power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).kishan singh tomar
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
General_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingGeneral_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingAnonymous
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfMedicoseAcademics
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 

Último (20)

power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Cone beam CT: concepts and applications.pptx
Cone beam CT: concepts and applications.pptxCone beam CT: concepts and applications.pptx
Cone beam CT: concepts and applications.pptx
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
General_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingGeneral_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_Wellbeing
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdf
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 

update on poor responder